Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYCETIN versus DIFICID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYCETIN versus DIFICID.
CHLOROMYCETIN vs DIFICID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation.
Fidaxomicin is a macrocyclic antibiotic that inhibits bacterial RNA polymerase, leading to RNA synthesis inhibition and cell death. It is bactericidal against Clostridioides difficile and has minimal systemic absorption.
50-100 mg/kg/day IV divided every 6 hours; maximum 4 g/day. Topical: apply to affected area 2-4 times daily.
200 mg (tablet) orally twice daily for 10 days.
None Documented
None Documented
1.5-4 hours in adults; prolonged to 3-7 hours in neonates and 4-12 hours in hepatic impairment; clinical context: dose adjustment required in liver disease.
11.7 hours (terminal half-life in healthy subjects); supports twice-daily dosing.
Renal: 5-10% unchanged; hepatic glucuronidation (90%) followed by renal elimination of metabolites; small biliary excretion (<5%) and fecal elimination.
Fecal (primarily as unchanged drug, ~44% of dose); renal (~1.6% unchanged, <1% as metabolites); biliary (minor).
Category C
Category C
Antibiotic
Antibiotic